ENG 
ESP 
Gene Therapy in Ophthalmology: The Future of Vision and Optogenetics
Ophthalmology is on the threshold of a therapeutic revolution driven by gene therapy. What was once science fiction is now a reality that is redefining the management of devastating diseases. The key for professionals is to understand the leap from one-off treatments to potentially long-lasting solutions.
Luxturna: The Starting Point and Ocular Privilege
The drug Luxturna (RPE65) proved that gene therapy is viable. Its success is largely due to the eye itself. It is an immune-privileged, anatomically isolated organ. This allows AAV vectors to be delivered safely and locally.
The most recent developments focus on how to get the therapy to the right place. Intravitreal (IVT) injection is now more effective. New vectors, such as the AAV2.7m8 capsid, can cross the inner limiting membrane. This greatly simplifies access to the outer retina, which used to require subretinal surgery.
The New Paradigm: Mutation-Agnostic Therapies
The most radical change is the arrival of therapies that work without correcting the original mutation:
- Optogenetics (MCO−010): This technology "rewires" the retina. It introduces light-sensitive proteins (opsins) into inner retinal cells (such as bipolar cells) that survive the disease. MCO-010, delivered by intravitreal injection, has shown promising results in retinitis pigmentosa. Patients achieved significant gains in visual acuity.
- Gene editing (CRISPR): This goes beyond gene replacement. CRISPR-Cas9 technology makes it possible to correct DNA inside the eye. The EDIT−101 trial marked a milestone by reporting functional improvement in Leber congenital amaurosis.
The Big Leap: From Rare Diseases to AMD
The focus has shifted to far more common diseases. Wet AMD is the next target. Gene therapies aim to eliminate the burden of repeated anti-VEGF injections. The goal is a single injection that produces anti-VEGF continuously for years.
The main obstacle to widespread adoption remains cost. Current pricing models cannot scale to millions of patients. The global ophthalmology community must find manufacturing and financing solutions that allow equitable access.
Where can you find us?
- YouTube: Subscribe to our channel for full episodes and exclusive content: https://www.youtube.com/@SamurEyePodcast
- Instagram: Follow us on Instagram to hear about upcoming topics, guests and highlights: @samureyepodcast
